News | August 14, 2022
Nectar Lifesciences posts Q1 FY23 consolidated PAT at Rs. 3.89 Cr
The company has reported total income of Rs. 403.38 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 403.38 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 4138.6 crores during the period ended June 30, 2022.
The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.
The company is focused on therapies such as skinceuticals, gastroenterology, neuropsychiatry, cardiac diabetes care etc.
The company has reported total income of Rs. 186.97 crores during the period ended June 30, 2022.
The company has posted net profit of Rs.39.71 crores for the Financial Year ended March 31, 2022.
The drug will be manufactured at the group’s topical facility at Ahmedabad
Pemetrexed for Injection has a market size of USD 1,236 mn (as per IQVIA MAT March’22)
The key categories include intimate wellness, skincare & hair care
_256_384.jpg)
The deal will be financed by Rs 300 crore of internal accruals and Rs 350 crore of borrowings
Subscribe To Our Newsletter & Stay Updated
